Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) EBITDA: 2019-2024

Historic EBITDA for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$105.1 million.

  • C4 Therapeutics' EBITDA fell 34.82% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.4 million, marking a year-over-year decrease of 14.70%. This contributed to the annual value of -$105.1 million for FY2024, which is 18.17% up from last year.
  • Per C4 Therapeutics' latest filing, its EBITDA stood at -$105.1 million for FY2024, which was up 18.17% from -$128.5 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' EBITDA peaked at -$66.3 million during FY2020, and registered a low of -$131.5 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$128.5 million (2023), whereas its average is -$121.7 million.
  • As far as peak fluctuations go, C4 Therapeutics' EBITDA tumbled by 94.50% in 2020, and later grew by 18.17% in 2024.
  • C4 Therapeutics' EBITDA (Yearly) stood at -$66.3 million in 2020, then declined by 27.68% to -$84.7 million in 2021, then plummeted by 55.33% to -$131.5 million in 2022, then rose by 2.32% to -$128.5 million in 2023, then climbed by 18.17% to -$105.1 million in 2024.